JP2018535394A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535394A5
JP2018535394A5 JP2018514414A JP2018514414A JP2018535394A5 JP 2018535394 A5 JP2018535394 A5 JP 2018535394A5 JP 2018514414 A JP2018514414 A JP 2018514414A JP 2018514414 A JP2018514414 A JP 2018514414A JP 2018535394 A5 JP2018535394 A5 JP 2018535394A5
Authority
JP
Japan
Prior art keywords
lcn2
patient
disease
level
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018514414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535394A (ja
JP6909208B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/052060 external-priority patent/WO2017049035A1/en
Publication of JP2018535394A publication Critical patent/JP2018535394A/ja
Publication of JP2018535394A5 publication Critical patent/JP2018535394A5/ja
Priority to JP2021110695A priority Critical patent/JP7153775B2/ja
Application granted granted Critical
Publication of JP6909208B2 publication Critical patent/JP6909208B2/ja
Priority to JP2022159196A priority patent/JP2023002583A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018514414A 2015-09-17 2016-09-16 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 Expired - Fee Related JP6909208B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021110695A JP7153775B2 (ja) 2015-09-17 2021-07-02 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2022159196A JP2023002583A (ja) 2015-09-17 2022-10-03 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220062P 2015-09-17 2015-09-17
US62/220,062 2015-09-17
PCT/US2016/052060 WO2017049035A1 (en) 2015-09-17 2016-09-16 Prediction of clinical response to il23-antagonists using il23 pathway biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021110695A Division JP7153775B2 (ja) 2015-09-17 2021-07-02 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測

Publications (3)

Publication Number Publication Date
JP2018535394A JP2018535394A (ja) 2018-11-29
JP2018535394A5 true JP2018535394A5 (https=) 2020-11-12
JP6909208B2 JP6909208B2 (ja) 2021-07-28

Family

ID=58289919

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018514414A Expired - Fee Related JP6909208B2 (ja) 2015-09-17 2016-09-16 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2021110695A Active JP7153775B2 (ja) 2015-09-17 2021-07-02 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2022159196A Pending JP2023002583A (ja) 2015-09-17 2022-10-03 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021110695A Active JP7153775B2 (ja) 2015-09-17 2021-07-02 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2022159196A Pending JP2023002583A (ja) 2015-09-17 2022-10-03 Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測

Country Status (13)

Country Link
US (1) US11016099B2 (https=)
EP (1) EP3349854A4 (https=)
JP (3) JP6909208B2 (https=)
KR (1) KR20180063127A (https=)
CN (2) CN108290058B (https=)
AU (1) AU2016323579A1 (https=)
BR (1) BR112018005175A2 (https=)
CA (1) CA2998349A1 (https=)
HK (1) HK1258292A1 (https=)
IL (1) IL257969A (https=)
MX (1) MX2018003376A (https=)
RU (1) RU2018113694A (https=)
WO (1) WO2017049035A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019113037A1 (en) * 2017-12-04 2019-06-13 Immusant, Inc. Measurement of ccl20 after gluten exposure
SG11202005305QA (en) * 2017-12-07 2020-07-29 Amgen Inc Method of treating idiopathic thrombocytopenia purpura (itp) with romiplostim
MX2020009265A (es) * 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
EP3793521A4 (en) * 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
US20200025776A1 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
IL326284A (en) 2018-09-24 2026-04-01 Janssen Biotech Inc A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody
US20220364171A1 (en) * 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
CN109337974B (zh) * 2018-12-14 2022-01-25 北京蛋白质组研究中心 一种检测银屑病的诊断标志物的试剂及其应用
MA54562A (fr) * 2018-12-18 2021-10-27 Janssen Biotech Inc Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
JP2022526493A (ja) * 2019-03-18 2022-05-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
EP3946592A4 (en) * 2019-03-26 2023-01-04 Astrazeneca Collaboration Ventures, LLC PATIENT POPULATIONS LIKELY TO BENEFIT FROM IL23 ANTAGONIST THERAPY
JP7778567B2 (ja) * 2019-04-17 2025-12-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド α４β７阻害薬及びＩＬ－２３阻害薬の併用療法
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
US20210079086A1 (en) * 2019-08-21 2021-03-18 Astrazeneca Collaboration Ventures, Llc Use of Brazikumab to Treat Crohn's Disease
EP4424381A3 (en) * 2019-10-18 2024-11-13 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
WO2021106453A1 (ja) * 2019-11-29 2021-06-03 東洋紡株式会社 組換えｃ反応性タンパク質
JP7758672B2 (ja) * 2019-12-20 2025-10-22 ノヴァロック バイオセラピューティクス， リミテッド 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
BR112022015996A2 (pt) * 2020-02-14 2022-10-11 Janssen Biotech Inc Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
CN111424086A (zh) * 2020-03-19 2020-07-17 上海交通大学 用于胃癌诊断及预后评估的生物标记物及应用和检测试剂盒
WO2021207725A1 (en) * 2020-04-10 2021-10-14 The Johns Hopkins University Lipocalin-2 assay for intestinal adaptation
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
US20230391863A1 (en) * 2020-10-23 2023-12-07 Hq Han Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
CN116782827A (zh) 2020-11-30 2023-09-19 明德拉公司 微针装置和方法以及皮肤病状测定
US20220373539A1 (en) * 2021-05-24 2022-11-24 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
US5455160A (en) 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
AU4790597A (en) 1996-11-01 1998-05-29 Nycomed Pharma As Process for the extraction of proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
US7226591B2 (en) 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
ES2316454T3 (es) 2000-08-24 2009-04-16 Genentech, Inc. Metodo de inhibicion de pap1 inducido por il-22.
WO2005086835A2 (en) 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
US20080199460A1 (en) 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
US20070203216A1 (en) 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
WO2007098065A2 (en) 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
WO2007149814A1 (en) 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17
GB0613470D0 (en) 2006-07-06 2006-08-16 Ares Trading Sa Protein
WO2008028044A2 (en) * 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20090123946A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
WO2009052400A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US20090269777A1 (en) 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
ES2475990T5 (es) 2007-11-15 2017-07-06 Bioporto Diagnostics A/S Uso diagnóstico de formas moleculares individuales de un biomarcador
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US7833720B2 (en) 2008-03-14 2010-11-16 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
US20100227775A1 (en) 2008-04-16 2010-09-09 Abbott Laboratories Immunoassays and kits for the detection of ngal
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
GB2464183A (en) 2008-09-19 2010-04-14 Singulex Inc Sandwich assay
US20100093552A1 (en) 2008-10-09 2010-04-15 Asit Panja Use and identification of biomarkers for gastrointestinal diseases
US20100105150A1 (en) 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
JP2012507723A (ja) * 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010129964A1 (en) 2009-05-08 2010-11-11 The Board Of Trustees Of The University Of Illinois Drug targets for prevention of arrhythmia in heart disease
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
EP3309556B1 (en) 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Methods for diagnosing irritable bowel syndrome
WO2011005779A2 (en) 2009-07-07 2011-01-13 University Of Southern California Biomarkers for the early detection of autoimmune diseases
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CA2781654A1 (en) 2009-11-25 2011-06-03 Hua Gong Novel genomic biomarkers for irritable bowel syndrome diagnosis
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
US8541180B1 (en) 2010-10-11 2013-09-24 Genova Diagnostics, Inc. Compositions and methods for assessing gastrointestinal health
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
BR112013017445A2 (pt) 2011-01-06 2016-08-23 Univ Illinois métodos de determinar a necessidade de um indivíduo para um desfibrilador cardíaco implantado (icd) e para uma terrapia antiarrítmica, de determinar o risco de um indivíduo para uma morte cardiáca súbita, para arritmias e para insuficiência cardíaca, de reduzir risco de morte cardíaca súbita em um indivíduo, kit, sistema, meio de armazenamento legível por computador, e, método implementado por um processador em um computador
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
EP2678448A4 (en) 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
AU2012249288C1 (en) 2011-04-29 2017-12-21 Lung Cancer Proteomics Llc Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2012158831A1 (en) 2011-05-16 2012-11-22 Prometheus Laboratories Inc. Performance of a biomarker panel for irritable bowel syndrome
NO336551B1 (no) 2011-06-21 2015-09-28 Magne Fagerhol Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve
NO20110895A1 (no) 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
KR20140067001A (ko) 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
CN104093310A (zh) * 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
WO2013132338A2 (en) 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
WO2013132347A2 (en) 2012-03-06 2013-09-12 Calpro As Improved elisa immunoassay for calprotectin
WO2013152114A1 (en) 2012-04-03 2013-10-10 The Regents Of The University Of Michigan Biomarker associated with irritable bowel syndrome and crohn's disease
PL2903691T3 (pl) * 2012-10-05 2019-10-31 Hoffmann La Roche Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit
EP3143401A4 (en) 2014-05-15 2017-10-11 Meso Scale Technologies, LLC Improved assay methods
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
EP3708679A1 (en) * 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
GB201521357D0 (en) 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
US11220541B2 (en) 2015-12-22 2022-01-11 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
WO2018089693A2 (en) 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
WO2018119626A1 (zh) 2016-12-27 2018-07-05 菲鹏生物股份有限公司 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒

Similar Documents

Publication Publication Date Title
JP2018535394A5 (https=)
JP7153775B2 (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP2019508370A5 (https=)
JP6849751B2 (ja) 可溶性ヒトｓｔ−２抗体およびアッセイ法
US20110243893A1 (en) Markers for determination of patient responsiveness
RU2018124603A (ru) Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23
RU2016134838A (ru) Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком
RU2016135417A (ru) Новый анализ для детектирования периостина человека
Mackintosh et al. Systemic sclerosis associated interstitial lung disease: a comprehensive overview
TWI655433B (zh) 川崎氏症之診斷與治療
JP2022512937A5 (https=)
Gvalani et al. Biomarkers in severe asthma: Identifying the treatable trait
JP2014513284A (ja) アルツハイマー病の静注用免疫グロブリン治療におけるサイトカイン濃度の使用
Fouladseresht et al. Anti-varicella zoster virus IgG and hsCRP levels correlate with progression of coronary artery atherosclerosis
JP2025533470A (ja) Ｈｂｖの診断、予後判定及び治療の方法並びに製品
Mukherjee et al. IL-13 signature in severe adult asthmatics with airway neutrophilia: A new endotype to treat!
JP2024512384A (ja) 汎発型膿疱性乾癬における抗ｉｌ－３６ｒ抗体による処置に関連したバイオマーカー
CN116323654A (zh) 涉及il-18的抗体的方法及疗法
Guerra et al. Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease
Tanapon Ussanawarong et al. The Immunogenicity of SARS-CoV-2 Vaccines in Thai Patients with Rheumatoid Arthritis: A Cross-Sectional Study from the National Health Thailand Program
WO2026058045A1 (en) Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
Nerella et al. Demystifying the three different types of COVID-19 associated multisystem inflammatory syndrome in children: Experience from a tertiary care hospital
WO2015166461A1 (en) Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
Dukler et al. Serum marker panel for detection of mucosal healing in vedolizumab treated patients with Ulcerative Colitis